Coagulation and wound repair during COVID-19.
COVID-19
SARS-CoV-2
coagulation
coronavirus
fibrinolysis
Journal
The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation
ISSN: 1557-3117
Titre abrégé: J Heart Lung Transplant
Pays: United States
ID NLM: 9102703
Informations de publication
Date de publication:
10 2021
10 2021
Historique:
received:
12
03
2021
revised:
21
05
2021
accepted:
08
06
2021
pubmed:
3
8
2021
medline:
3
11
2021
entrez:
2
8
2021
Statut:
ppublish
Résumé
While COVID-19 is best known as a respiratory infection, SARS-CoV-2 causes systemic disease manifestations including coagulopathies. Both dysregulated extracellular matrix remodeling pathways and circulating coagulation proteins are hallmarks of severe COVID-19 and often continue after the resolution of acute infection. Coagulation proteins have proven effective as biomarkers for severe disease and anticoagulants are a mainstay of COVID-19 therapeutics in hospitalized patients. While much knowledge has been gained about the role of clotting pathway activation in COVID-19, much remains to be elucidated in this complex network of signaling pathways.
Identifiants
pubmed: 34334300
pii: S1053-2498(21)02359-7
doi: 10.1016/j.healun.2021.06.006
pmc: PMC8195688
pii:
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1076-1081Subventions
Organisme : NIAID NIH HHS
ID : R01 AI153602
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL160046
Pays : United States
Organisme : NIAID NIH HHS
ID : R21 AI145372
Pays : United States
Informations de copyright
Copyright © 2021 International Society for Heart and Lung Transplantation. Published by Elsevier Inc. All rights reserved.